18 The addition of eculizumab, which neutralises human complement C5, to IVIg in one small‐controlled trial showed a trend towards improvement 19 which needs to be confirmed in larger studies.
← all excerpts
IqYmune® is an effective maintenance treatment for multifocal motor neuropathy: A randomised, double-blind, multi-center cross-over non-inferiority study vs Kiovig®-The LIME Study.
1
—
—